Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Total Valuation
Lantern Pharma has a market cap or net worth of $21.83M. The enterprise value is -$4.32B.
Market Cap$21.83M
Enterprise Value-$4.32B
Share Statistics
Lantern Pharma has 11,254,697 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,254,697
Owned by Insiders19.24%
Owned by Institutions11.96%
Financial Efficiency
Lantern Pharma’s return on equity (ROE) is -2.62 and return on invested capital (ROIC) is -0.27%.
Return on Equity (ROE)-2.62
Return on Assets (ROA)-1.55
Return on Invested Capital (ROIC)-0.27%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-713.31M
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lantern Pharma is ―. Lantern Pharma’s PEG ratio is 0.00002.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio0.00002
Income Statement
In the last 12 months, Lantern Pharma had revenue of 0.00 and earned -17.12B in profits. Earnings per share was -1.57.
Revenue0.00
Gross Profit-17.28K
Operating Income-17.98M
Pretax Income-17.12M
Net Income-17.12B
EBITDA-17.96M
Earnings Per Share (EPS)-1.57
Cash Flow
In the last 12 months, operating cash flow was -15.68B and capital expenditures -11.00, giving a free cash flow of -15.68B billion.
Operating Cash Flow-15.68B
Free Cash Flow-15.68B
Free Cash Flow per Share-1.39K
Dividends & Yields
Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.20
52-Week Price Change-34.01%
50-Day Moving Average2.49
200-Day Moving Average3.52
Relative Strength Index (RSI)45.92
Average Volume (3m)1.01M
Important Dates
Lantern Pharma upcoming earnings date is May 5, 2026, Before Open (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 5, 2026
Ex-Dividend Date―
Financial Position
Lantern Pharma as a current ratio of 2.40, with Debt / Equity ratio of 1.20%
Current Ratio2.40
Quick Ratio2.40
Debt to Market Cap2.38
Net Debt to EBITDA241.87
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lantern Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lantern Pharma EV to EBITDA ratio is 240.03, with an EV/FCF ratio of 0.28.
EV to Sales0.00
EV to EBITDA240.03
EV to Free Cash Flow0.28
EV to Operating Cash Flow0.28
Balance Sheet
Lantern Pharma has $10.12B in cash and marketable securities with $78.54M in debt, giving a net cash position of $10.04B billion.
Cash & Marketable Securities$10.12B
Total Debt$78.54M
Net Cash$10.04B
Net Cash Per Share$892.13
Tangible Book Value Per Share$599.58
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lantern Pharma is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.00
Price Target Upside727.81% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast1.18%